Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

123.24 -0.33 (-0.27%)
Streaming Delayed Price Updated: 10:44 AM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday? ↗
Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant improvements in hypertension and hyperglycemia. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. ↗
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. 
Via Chartmill
News headline image
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Completes Enrollment in Phase 4 CATALYST Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Recap: Corcept Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter ↗
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the... 
Via Benzinga
News headline image
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Earnings Preview: Corcept Therapeutics ↗
 
Via Benzinga
News headline image
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗
In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition. 
Via Chartmill
News headline image
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. ↗
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
News headline image
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday? ↗
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes. 
Via Benzinga
News headline image
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. 
Via Chartmill
News headline image
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Appoints Roberto Vieira as President, Oncology
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued. 
Via Chartmill
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.